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Chronic obstructive pulmonary disease (COPD) is characterised by chronic inflammation in
airways and lung parenchyma. CD8þ T-lymphocytes, crucial effector and regulatory cells in
inflammation, are increased in the central and peripheral airways in COPD. The aim of this
study was to assess the role of apoptosis in the accumulation of CD8þ T-lymphocytes within
the airway wall in COPD. We examined the submucosa of transverse sections of central and
peripheral airways from post-operative tissues from non-smokers (n Z 16), smokers with
normal lung function (nZ 16), smokers with mild/moderate COPD (nZ 16), and smokers with
severe/very severe COPD (nZ 9). TUNEL and immunohistochemistry techniques were used to
identify apoptosis and cell phenotype, respectively. The percentage of apoptotic CD8þ
T-lymphocytes was significantly lower (p < 0.0001) in smokers with mild/moderate COPD than
in non-smokers, smokers with normal lung function, and smokers with severe/very severe
COPD, and was positively related to values of FEV1 and FEV1/FVC ratio, both in central and
in peripheral airways. These data suggest that reduced apoptosis of CD8þ T-lymphocytes
may be an important mechanism that contributes to the accumulation of these cells in the
airway submucosa in smokers with mild/moderate COPD.
ª 2011 Elsevier Ltd. All rights reserved.1 680 9125; fax: þ39 091 680 9122.
nr.it (M. Gjomarkaj).
1 Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is
a complex disease characterized by a chronic innate and
adaptive inflammatory immune responses to long-term
exposure to inhaled toxic gases and particles. Although
environmental pollution contributes to this response,
cigarette smoke is the major risk factor for the devel-
opment of COPD, cigarette smokers constituting
more than 90% of all COPD patients in developed
countries.1
This inflammatory immune process affects both airways
and lung parenchyma, and the cell types mainly involved
in this phenomenon include neutrophils, macrophages,
and T-cells.2 CD8þ T-lymphocytes appear to play a crucial
role in orchestrating the inflammatory response and have
been related to disease progression.3 The number of CD8þ
T-lymphocytes is increased both in central and in
peripheral airways4,5 as well as in lung parenchyma and
pulmonary arteries6 in COPD. CD8þ T-lymphocytes
represent an essential part of the adaptive immune
response to viral infections,7 therefore the homing of
CD8þ T-lymphocytes into the airways might also be
promoted by the presence of respiratory viral infections,
very common event in patients with COPD,8 and it might
depend on initial activation as well as adhesion and
selective chemotaxis9,10 of these cells. Despite these
observations, the molecular mechanisms by which the
CD8þ T-lymphocytes accumulate in the airways of
patients with COPD are presently not well understood.
Inflammatory cells may accumulate in the airways through
a number of mechanisms including increased recruitment
from the bloodstream through chemotaxis10,11 and local
proliferation12 on the one hand, and/or by decreased
removal through inefficient clearance by macrophages13
or through reduced apoptosis. In multicellular organisms,
apoptosis is essential for development, immune functions,
and for the maintenance of homeostasis. Apoptosis is also
involved in the control of the “tissue load” of immune
effector cells at inflamed sites and it tends to limit
inflammatory tissue injury by promoting resolution rather
than progression of inflammation.14 It has also been shown
that decreased or suppressed apoptosis of immune
effector cells in inflamed tissues may contribute to
chronic inflammation. In rheumatoid arthritis the active
suppression of T-cell death by the synovial microenviron-
ment is an important mechanism for the persistence of
T-cell infiltrates in chronically inflamed joints.15 More-
over, delayed eosinophil apoptosis in nasal polyps has
been indicated as a novel mechanism by which eosinophils
specifically accumulate in polipoid tissue.16 Our group has
previously observed reduced apoptosis of memory T-cells
in the airway wall of patients with asthma.17 However,
little is known about survival and apoptosis of inflamma-
tory cells in the airways of patients with COPD. In the
present study, we therefore examined the role of
apoptosis in the persistent accumulation of CD8þ
T-lymphocytes in the airways of patients with COPD. We
evaluated this phenomenon by using surgical lung
samples, at different levels of the airways and at different
stages of the disease.Materials and methods
Subjects
Subjects recruited into the present study were categorized
into the following four groups: asymptomatic non-smoking
subjects (never smoked) with normal lung function (control
non-smokers; n Z 16); asymptomatic smokers with normal
lung function (control smokers; nZ 16); smokers with mild
or moderate COPD (n Z 16; 5 mild and 11 moderate) and
smokers with severe or very severe COPD (n Z 9; 3 severe
and 6 very severe), based on Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria18 stages IeII and
stages IIIeIV, respectively. Control smokers and smokers
with COPD included both current and former smokers.
All former smokers had stopped smoking for more than
one year.
Lung specimens were obtained at surgery either from
patients undergoing lobectomy or pneumonectomy for
peripheral carcinoma in the mild/moderate COPD cases or
control subjects, or from subjects undergoing lung trans-
plantation for emphysema in the severe/very severe COPD
cases.
During the week before surgery, each subject underwent
chest radiography, electrocardiogram, routine blood tests,
skin prick tests with common allergen extracts, pulmonary
function tests, and an interview regarding respiratory
symptoms, medications used and smoking history. All mild/
moderate COPD cases used bronchodilators and all severe/
very severe COPD cases used, in addition to bronchodila-
tors, regular inhaled corticosteroid therapy and systemic
corticosteroid therapy during the frequent exacerbations.
During the month preceding surgery, COPD cases had no
exacerbations and all subjects had no acute upper respi-
ratory tract infections. All subjects were non-atopic
(negative skin prick tests for common allergen extracts)
and had no history of asthma or allergic rhinitis.
The present study was performed with approval of Sir
Charles Gairdner Hospital’s Ethics Committee (Nedlands,
Australia), and informed written consent was obtained for
each subject prior to surgery.
Pulmonary function tests
Pulmonary function tests were performed according to
standard methods19 and included measurements of forced
expiratory volume in 1 s (FEV1), and forced vital capacity
(FVC). Fixed airway obstruction was defined according to
recent guidelines20 as a ratio of FEV1 to FVC of less than 70%
predicted, with FEV1 reversibility of less than 12% after
inhalation of 200 mg salbutamol.
Tissue preparation
Tissue blocks were taken from transverse central airways
and subpleural parenchyma (for peripheral airways) of the
lobe obtained at surgery, avoiding areas close to the tumor
in control groups and mild/moderate COPD cases who
underwent lung resection for carcinoma. The same labo-
ratory procedure was followed for samples from lungs
CD8þ T-lymphocyte apoptosis in COPD 1493recovered during lung transplantation for severe/very
severe COPD cases. Samples were freshly fixed in formalin,
dehydrated, and embedded in paraffin wax. 4 mm-thick
whole transverse sections were cut, mounted on charged
slides, dewaxed, rehydrated, and processed for the
detection of apoptosis in CD8þ T-lymphocytes.
Detection of apoptosis in CD8D T-lymphocytes
Apoptosis of CD8þ T-lymphocytes was detected by
combining the terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling (TUNEL) and the immu-
nohistochemistry techniques to identify cell apoptosis and
cell phenotype, respectively.21 Sections were first stained
by the TUNEL technique which detects DNA strand breaks in
cells undergoing apoptosis, using a commercial kit (Roche
Applied Science, Penzberg, Germany) following the manu-
facturer’s instructions. Briefly, terminal deoxynucleotidyl
transferase (TdT) was used to incorporate fluorescein-
deoxyuridine (dUTP) at sites of DNA cleavage. Incorpo-
rated fluorescein was detected by anti-fluorescein antibody
conjugated with horse-radish peroxidase (POD). The stain-
ing was achieved with 3,30-diaminobenzidine (DAB)-sub-
strate solution leaving a dark-brown nuclear end-product.
Some slides were incubated with DNAse I (Roche Applied
Science) (1000 U/ml, 15 min, room temperature) to induce
DNA strand breaks or in buffer without TdT enzyme or dUTP
as positive and negative controls, respectively.
To identify CD8þ T-lymphocytes, the same sections were
subsequently stained with a monoclonal mouse anti-human
CD8 antibody (MAb) (clone C8/144B; M7103, Dako,
Glostrup, Denmark), diluted 1:50. This antibody specifically
labels cytotoxic/suppressor T-cells.22
MAb binding was revealed by labelled streptavidin biotin-
alkaline phosphatase method (LSAB2 System-AP; Dako), and
New Fuchsin as chromogenic substrate, leaving a red cyto-
plasmic end-product. To expose the immunoreactive
epitope of cell marker, the sections were pre-incubated in
Trizma-buffered saline (SigmaeAldrich, St. Louis, MO, USA),
pH 9.1, at 92 C for 45 min. Negative controls were per-
formed by omitting the primary antibody or by using an
isotype control antibody (IgG1) from the same species.
Human tonsil tissue was used as a positive control. Sections
were finally counterstained with haematoxylin.
Morphometric analysis and cell counts
Airway images were obtained by a light microscope (Leitz
Biomed; Leica, Cambridge, UK) at 400 magnification,
connected to a video recorder linked to a computerized
image system (Quantimet 500 Image Processing and Anal-
ysis System, Qwin V0200B software; Leica). In all airway
transverse sections, the internal perimeter, defined by the
basement membrane perimeter (Pbm), and the submucosa
area (region between basement membrane and inner edge
of smooth muscle layer) were measured. Airways were
assigned to two groups according to their Pbm: central
(Pbm>6 mm) and peripheral (Pbm<6 mm).10 Internal
perimeter rather than airway diameter was selected as
a criterion to describe airway size because it remains
constant irrespective of airway constriction or relaxation.23Two to five central airways with a full perimeter and two
parenchymal sections with approximately six peripheral
airways per section were examined for each patient.
Airways with a short/long diameter ratio less than one-third
were excluded from the study, as being tangentially cut.
For each airway section, both apoptotic and non apoptotic
CD8þ T-lymphocytes were counted in the submucosa, along
the entire length of the basement membrane per unit area
(mm2), and apoptotic CD8þ T-lymphocytes were expressed
as percentage of apoptotic CD8þ T-lymphocytes over total
CD8þ T-lymphocytes in the examined airway submucosa.
The final result per subject was the average of the number
of apoptotic CD8þ T-lymphocytes present in each airway of
that patient. Slides were coded and blindly evaluated by
two independent investigators (L.S. and E.P.) without
knowledge of clinical and functional data.
Immunofluorescence microscopy
Double immunofluorescence staining was performed on
formalin-fixed paraffin-embedded tissue sections from
samples of smoking controls and smokers with mild/
moderate COPD to evaluate the co-localization of CD8 and
Annexin V or CD4 and Annexin V. Immunostainings were
performed using monoclonal mouse anti-human CD8 (clone
C8/144B; Dako) or monoclonal mouse anti-human CD4
(clone 4B12; Dako) antibodies. Double labelling was per-
formed using both a secondary fluorescein isothiocyanate
(FITC)-conjugated anti-mouse polyclonal rabbit IgG anti-
body (SigmaeAldrich) and phycoerythrin (PE)-conjugated
Annexin V (BD Biosciences Pharmingen, San Diego,CA, USA)
in the same section. Slides were analysed by a fluorescence
microscope (Axioscop 2; Zeiss, Heidelberg, Germany).
Statistical analysis
Group data were expressed as mean and SEM or as median
and 25th e75th percentiles where appropriate. Analysis of
variance (ANOVA) and unpaired Student’s t-test for clinical
data, and KruskalleWallis test for histological data were
used to analyse differences between subject groups.
ManneWhitney U test was performed for comparisons
between two groups, if initial KruskalleWallis test indi-
cated significance. Spearman’s rank correlation test was
used for the correlations between histological and func-




The demographic and clinical characteristics of the four
subject groups are shown in Table 1. Sex ratio and mean age
were similar in all four groups. As expected from the selec-
tion criteria, mild/moderate COPD cases (GOLD stages I/II)
had significantly lower values of FEV1 (% predicted) and of
FEV1/FVC ratio (%) than smoking controls and non-smoking
controls. Moreover, severe/very severe COPD cases (GOLD
stages III/IV) had significantly lower values of FEV1 (%
Table 1 Subject characteristics.







Subjects examined, n 16 16 16 9
Sex, male/female, n 10/6 11/5 11/5 6/3
Age, yrs 51  6 48  5 64  3 45  3
Smoking history, pack/yrsc 0 49  7
Current/former smokers, n 0/0 15/1 11/5 0/9
FEV1, % pred 107  4 90  2 74  3b 25  4a
FEV1/FVC, % 94  2 84  2 62  1b 31  2a
Data are expressed as absolute number or mean  SEM.
a Significantly different from mild/moderate COPD cases, smoking controls and non-smoking controls (p < 0.05).
b Significantly different from smoking controls and non-smoking controls (p < 0.05).
c It was not possible to obtain the precise pack-year history of smoking controls and severe/very severe COPD cases.
1494 L. Siena et al.predicted) and FEV1/FVC ratio (%) thanmild/moderate COPD
cases, smoking controls, and non-smoking controls.
Airway characteristics
The morphometric characteristics of the airways examined
are shown in Table 2. In each airway size category there
were no statistically significant differences in the mean
Pbm among the four subject groups.
Evaluation of CD8D T-lymphocyte apoptosis
Apoptotic CD8þ T-lymphocytes were identified by co-
localization of the dark-brown nuclear staining generated
by the TUNEL technique with red cytoplasmic staining
generated by the CD8 immunoreactivity. Apoptosis was also
evaluated on the basis of the morphologic appearance of
apoptosis. Specifically, at light microscopy observation,
chromatin condensation and nuclear fragmentation were
used to identify apoptotic cells (Figs. 1 and 2).
The median densities of all CD8þ T-lymphocytes,
including those undergoing apoptosis, and the median
densities of apoptotic CD8þ T-lymphocytes in the submu-
cosa of central and peripheral airways, in the four subject
groups, are shown in Table 3. The median percentage of
apoptotic CD8þ T-lymphocytes in the submucosa of central
airways was significantly lower (p < 0.0001) in mild/
moderate COPD cases than in non-smoking controls,Table 2 Morphometric characteristics of the airways.




Central airways 15.17  1.28 15.26  2.1
Peripheral airways 2.62  0.19 2.42  0.1
Data are expressed as mean  SEM.
Pbm: basement membrane perimeter.
a No statistically significant differences between groups.smoking controls and severe/very severe COPD cases
(median, 25the75th percentiles: 12, 10e18; 40, 37e46; 36,
33e41; 36, 30e47 respectively) (Fig. 3). No significant
differences were found in the percentage of apoptotic
CD8þ T-lymphocytes between severe/very severe COPD
cases, smoking controls, and non-smoking controls (Fig. 3).
Similarly, the median percentage of apoptotic CD8þ T-
lymphocytes in the submucosa of peripheral airways was
significantly lower in mild/moderate COPD cases than in
non-smoking controls or smoking controls (p < 0.0001) and
severe/very severe COPD cases (p Z 0.0001) (median,
25the75th percentiles: 17, 12e23; 41, 32e49; 34, 31e39;
34, 30e43 respectively) (Fig. 4).
Fig. 5, AeC shows a double immunofluorescence analysis
from a control smoker demonstrating the presence of
Annexin V in CD8þ T-lymphocytes. The number of CD8þ T-
lymphocytes that co-localized Annexin V was lower in
smokers with mild/moderate COPD than in smoking controls
(data not shown). Similar results were observed for the
presence of Annexin V in CD4þ T-lymphocytes (Fig. 5,
DeF), confirming that the survival of both CD8þ and CD4þ
T-lymphocytes is similarly regulated.
Correlationsbetweenhistological and functional data
When all studied subjects were considered together, no
significant correlation was observed between apoptosis of





0 12.28  1.52 12.93  1.05
6 2.73  0.27 2.86  0.32
Figure 1 Microphotographs of a central airway submucosa from a smoker with mild COPD, showing double staining by TUNEL
(brown color) and anti-CD8 (red color) (panel A), single staining by TUNEL (panel B), single staining by anti-CD8 (panel C),
and negative control for non specific binding both omitting the TdT enzyme and using an isotype-matched antibody (panel D).
Haematoxylin counterstaining. Representative experiment. In panel A, arrows indicate CD8þ T-lymphocytes (red cytoplasmic
staining) with TUNEL negative nuclei (haematoxylin staining) and normal morphology; arrow heads indicate CD8þ T-lymphocytes
with TUNEL þ nuclei (dark-brown nuclear staining) and apoptotic morphology, including chromatin condensation and nuclear
fragmentation; open arrow heads indicate CD8 negative cells with TUNEL þ nuclei. Original magnification: X 400. (For interpre-
tation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
CD8þ T-lymphocyte apoptosis in COPD 1495severe/very severe COPD cases were excluded from the
analysis, significant positive correlations were observed
between the percentage of apoptotic CD8þ T-lymphocytes
and the values of FEV1 (% predicted) and FEV1/FVC ratio,
both in central and in peripheral airways (Fig. 6).
Moreover, a significant negative correlation was observed
between the total number of CD8þ Telymphocytes and the
percentage of apoptotic CD8þ T-lymphocytes, both in
central and peripheral airways (rhoZ 0.50, p< 0.0001 and
rhoZ  0.40, pZ 0.002 respectively).
Discussion
This study shows that, in the submucosa of both central and
peripheral airways, there is a reduction of the percentageFigure 2 High power view of CD8þ T-lymphocytes with CD8 immu
nucleus (haematoxylin staining) and B) TUNEL þ nucleus (dark-brow
nucleus and D) TUNEL þ nucleus. Typical apoptotic morphology i
nuclear fragmentation. Original magnification: X 1000. (For interp
reader is referred to the web version of this article.)of CD8þ T-lymphocytes undergoing apoptosis in smokers
with mild to moderate COPD compared with non-smokers
and smokers with normal lung function, and cases of
severe/very severe COPD, and this result correlates with
the degree of airflow obstruction. To our knowledge, this
is the first study examining apoptosis of inflammatory cells
in the entire inner wall in transverse sections of both
central and peripheral airways in COPD.
In the present study, CD8þ T-lymphocyte apoptosis was
evaluated by the TUNEL technique and morphological
analysis. Different complex pathways are involved in cell
apoptosis and therefore different regulatory factors (pro-
or anti-apoptotic proteins) might be quantified. The
expression of such markers might correlate with the
occurrence of apoptosis but it does not precisely measurenoreactivity (red cytoplasmic staining) with A) TUNEL negative
n nuclear staining). CD8 negative cells with C) TUNEL negative
s shown in B) and D): shrinkage, chromatin condensation and
retation of the references to colour in this figure legend, the
Table 3 CD8+ T-lymphocytes in submucosa of the airways.









Total cells/mm2 19 (11e29) 172 (130e227)a 182 (99e224)a 45 (41e62)b
Apoptotic cells/mm2 8 (5e11) 61 (51e76) 20 (15e31)c 19 (16e23)
Peripheral airways
CD8+ T-lymphocytes
Total cells/mm2 21 (9e40) 96 (68e125)a 154 (120e245)a 82 (42e98)d
Apoptotic cells/mm2 7 (3e18) 34 (20e51) 25 (18e39) 26 (20e35)
Data are expressed as median and 25the75th percentiles.
a Significantly different from non-smokers (p < 0.0001).
b Significantly different from non-smokers (p Z 0.005).
c Significantly different from smokers (p < 0.0001).
d Significantly different from non-smokers (p Z 0.003).
1496 L. Siena et al.the ongoing apoptosis. We used here the TUNEL technique
because it is the most useful technique to detect cell
apoptosis in paraffin-embedded tissues and it has been used
and validated in many studies.17,24 In addition, this tech-
nique offers the major advantages of revealing early DNA
breaks during apoptosis, measuring the number of
apoptotic cells and simultaneously identifying, by immu-
nohistochemistry, the phenotype of the cells undergoing
apoptosis within a heterogeneous population.25 We also
used morphological analysis as a control method to confirm
cell apoptosis. Morphological cell changes during apoptosisFigure 3 Apoptotic (TUNELþ) CD8þ T-lymphocytes in
submucosa of central airways in non-smoking and smoking
controls, mild/moderate COPD cases and severe/very severe
COPD cases. Results are expressed as percent of total CD8þ
T-lymphocytes that are apoptotic. Horizontal bars inside boxes
represent the median values and limits of boxes represent the
25th and 75th percentiles. P values (inside the figure) repre-
sent the results of ManneWhitney U test analyses. Overall
comparison was made by KruskaleWallis test (p < 0.0001).have been demonstrated to be unique and they should be
considered “deciding factors” when identifying the type of
cell death.26 Accordingly, apoptosis was originally defined
on the basis of the analysis of cell morphology. In this study,
the evaluation of cell morphology allowed us to differen-
tiate apoptotic cells, characterized by cell shrinkage,
plasma membrane blebbing, chromatin condensation with
margination to the nuclear membrane, nuclear fragmen-
tation, and formation of apoptotic bodies,27 from necrotic
cells that die by swelling and rupturing,26 and from
damaged cells. We found that the majority ofFigure 4 Apoptotic (TUNELþ) CD8þ T-lymphocytes in
submucosa of peripheral airways in non-smoking and smoking
controls, mild/moderate COPD cases and severe/very severe
COPD cases. Results are expressed as percent of total CD8þ
T-lymphocytes that are apoptotic. Horizontal bars inside boxes
represent the median values and limits of boxes represent the
25th and 75th percentiles. P values (inside the figure) repre-
sent the results of ManneWhitney U test analyses. Overall
comparison was made by KruskaleWallis test (p < 0.0001).
Figure 5 Immunofluorescence analysis in a central airway submucosa from a control smoker, showing the presence of Annexin V
(A and D; red) in CD8þ and CD4þ T-lymphocytes (B and E respectively; green); overlay image of A and B (C; yellow/orange) and of D
and E (F; yellow/orange) as indicated by the arrows. Original magnification: X 400. Representative experiment. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
CD8þ T-lymphocyte apoptosis in COPD 1497TUNEL þ CD8þ T-lymphocytes showed the morphological
changes of apoptosis, confirming that the combination of
these two techniques was indeed the best way to identify
the apoptotic CD8þ T-lymphocytes.
In COPD, CD8þ T-lymphocytes are thought to act as
effector cells of the adaptive immune response, repre-
senting the anti-viral arm of the immune system.7 They may
also recognize auto-antigens originating in the lung and
induced by the cigarette smoke exposure.28 Most activated
CD8þ T-lymphocytes reside in the submucosa29 where they
exert effector functions. The submucosa is close to the
airway lumen where inhaled agents may trigger an inflam-
matory response in the adjacent tissue. Through theirFigure 6 Regression analysis between FEV1 (A and C), FEV1/FV
lymphocytes in the submucosa of central airways (A and B) and pe
smokers, and smokers with milde/moderate COPD. Spearman’s ran
p < 0.0001; in C rho Z 0.52, p Z 0.0004; in D rho Z 0.58, p < 0.effector functions, CD8þ T-lymphocytes play an important
role in the amplification of the inflammatory response and
in the tissue damage and remodeling processes that
determine the functional alterations in COPD. Specific
chemokine receptors and adhesion molecules are involved
in the recruitment of CD8þ T-lymphocytes into the airways
during inflammation and increased recruitment may
represent a mechanism by which CD8þ T-lymphocytes
accumulate within the airway wall, in COPD.9,10 Moreover,
it has been also suggested that chronic inflammation in the
airways might result from reduced apoptosis of inflamma-
tory cells, with the consequence of their accumulation at
the site of inflammation.30 Our results showing reducedC (B and D) values and the percentage of apoptotic CD8þ T-
ripheral airways (C and D) of all control non-smokers, control
k correlations. (In A rho Z 0.60, p < 0.0001; in B rho Z 0.72,
0001).
1498 L. Siena et al.apoptosis of CD8þ T-lymphocytes in smokers with mild to
moderate COPD suggest that this mechanism of accumula-
tion and persistence of these inflammatory cells within the
airway wall is present also in this disease. Hodge et al.31
described increased apoptosis of peripheral blood T-cells
in COPD, whereas we show here decreased apoptosis of
T-cells in the airway submucosa in COPD. This suggests that
mechanisms that prevent apoptotic cell death of CD8þ
T-lymphocytes might depend on survival factors present in
the inflammatory microenvironment of the airways.
IL (interleukin)-6 appears to be a survival factor for
T-cells,32 and its expression is increased in bron-
choalveolar lavage (BAL)33 and sputum34 in COPD. There
is clear evidence for nuclear factor (NF)-kB activation in
bronchial epithelial cells and in CD8þ T-lymphocytes in
the bronchial submucosa of COPD patients35 and NF-kB is
not only a central transcription factor in inflammatory
cell network, but it also stimulates cell survival by control
of expression of anti-apoptotic proteins, including B
cell lymphoma(Bcl)-2 and inhibitor of apoptosis proteins
(IAPs).36 Moreover, it has been reported that T-cell
survival is mediated via receptors, such as 4-1 BBL, that
are known to signal via NF-kB pathways.37 These concepts,
together with the present findings that CD8þ T-lympho-
cytes show decreased apoptosis in the airway submucosa
in mild/moderate COPD cases, strongly support the pres-
ence of a tight link between a reduced inflammatory cell
apoptosis and the persistence of airway inflammation. In
addition, the findings of the present study are in line
with those of other work from our group24 assessing leptin
expression in bronchial biopsies from smokers with or
without COPD. In that study we showed that in the
submucosa, the percentage of CD8þ T-lymphocytes
expressing leptin and its receptor was higher in smokers
with COPD than in smokers with normal lung function.
Leptin expression was paralleled by the absence in the
COPD cases, and by a low percentage in control smokers,
of apoptotic CD8þ T-lymphocytes. As leptin exerts anti-
apoptotic effects on T-lymphocytes38 by upregulating
the Bcl-xL through its receptor, these findings suggest
that, in COPD, leptin might act within the airway wall as
a survival factor for CD8þ T-lymphocytes contributing to
their accumulation in the airway submucosa of COPD
patients.
We had also evaluated the apoptosis of CD4þ
T-lymphocytes in some samples of each subject group and
we found a reduction of apoptotic CD4þ T-lymphocytes in
smokers with mild/moderate COPD compared with control
subjects and with severe/very severe COPD (data not
shown). These findings suggest that CD4þ T-lymphocytes
show a reduced cell apoptosis as well supporting the
hypothesis that survival factors present in the inflammatory
microenvironment of airways in COPD patients may prevent
apoptotic cell death.
Hodge et al. described increased apoptosis of T-cells
also in the BAL of COPD patients39 whereas no previous
assessment of the CD8þ T-lymphocytes apoptosis directly
in the inner airway wall of COPD patients has never been
done, as we have done in this study. So, our findings suggest
the presence of a different regulation of inflammatory cells
in anatomically and functionally different compartments
such as airway tissue, airway lumen and peripheral blood. Asimilar compartimentalised regulation of the inflammatory
responses has previously been described with regard to the
number of inflammatory cells and to the concentration of
inflammatory mediators40,41
In a recent study, Barcelo` et al.42 demonstrated that in
smokers with COPD, the percentage of CD8þ CD45RAþ
T-lymphocytes lacking the CD28 molecule was increased
compared with smokers with normal lung function. As T-cell
maturation-activation involves sequential expression of
CD45RA (naı¨ve T-cells), CD45RO (memory T-cells) and
CD45RA (effector/cytotoxic T-cells),43 the loss of CD28 in
CD8þ CD45RAþ T-lymphocytes suggests a final maturation-
activation state of CD8þ T-lymphocytes with a correspond-
ing higher potential for tissue injury in COPD. Experiments
to monitor herpes virus-specific CD8þ T-cells responses
in humans,44 showed that CD8þ CD45RA þ memory T-cells
expressed high levels of Bcl-2 and Bcl-xL, suggesting
low susceptibility to apoptosis. Barcelo` et al.42 analysed
CD8þ T-lymphocytes from BAL. It is currently unknown
whether CD8þ T-lymphocytes in other lung compartments
(bronchial mucosa, interstitium) show analogous pheno-
typic characteristics. If so, it might partly explain the CD8þ
T-lymphocyte resistance to apoptosis, that we observed in
mild to moderate COPD. On the other hand, resting memory
T-cells that are thought to maintain the "pool" of memory
T-cells in peripheral tissues, are more resistant to apoptosis
partially because of increased Bcl-2 expression.44
Unlike the mild/moderate COPD cases, those with
severe/very severe COPD did not show decreased apoptosis
of CD8þ T-lymphocytes compared with smoking controls
and non-smoking controls. One explanation for this appar-
ently contradictory result might be that the severe/very
severe COPD cases recruited into this study regularly used
corticosteroids which are known to increase apoptosis of
T-cells.45 Since all severe/very severe COPD cases who
had undergone lung surgery were often using corticosteroid
therapy, it was not possible to enrol subjects with severe
COPD without corticosteroid therapy in this study. In
addition, other possible explanations for the increased
CD8þ T-lymphocytes apoptosis in severe/very severe
patients, include the fact that in severe COPD there is
extensive destruction of airways and we measured
processes in the remaining airways, where the inflamma-
tory and remodelling processes may be different. Moreover,
the severe COPD patients are a different population with
systemic inflammation, cachexia and high levels of TNFa,
a cytokine with proapoptotic effects.
Our results however are consistent with those of Di
Stefano et al.9 who showed decreased numbers of CD8þ
T-cells in bronchial biopsies from cases of severe COPD
compared with cases of mild/moderate COPD, but they
appear to be in contrast with those of Hogg et al3 who
showed an increased accumulated volume of CD8þ T-cells
in peripheral airways and an increased number of airways
with CD8þ T-cells, in relation to decreased FEV1. Possible
explanations for this discrepancy include the different
sources of lung tissue (lung transplantation in our study and
lung volume reduction surgery in Hogg) as well as the
different methods of quantifying CD8þ cells and the fact
that we counted CD8þ T-cells in the submucosa of
peripheral airways while Hogg et al. examined CD8þ T-cells
in the total wall thickness showing that in patients with
CD8þ T-lymphocyte apoptosis in COPD 1499severe disease, lymphocytes also accumulate in lymphoid
follicles in the advential layer.
Accordingly to previous studies, we observed a signifi-
cant negative correlation between CD8þ T-cell total
number and lung function, in peripheral airways. Differ-
ently, we did not observe any correlations in the central
airways (data not shown). This lack of correlation in the
central airways may be due to the finding that numbers of
CD8þ T-lymphocyte were equally elevated in both smokers
with normal lung function and smokers with mild/moderate
COPD, as other authors had previously reported.9,46
We also found no significant differences in apoptotic
CD8þ T-lymphocyte percentages between controls who
were smokers or non-smokers. This finding suggests that
mechanisms other than apoptosis, such as increased
migration into the airway wall, may contribute to persistent
accumulation of CD8þ T-lymphocytes in the airway
submucosa of smokers with normal lung function. Alterna-
tively, smoking-related defective efferocytosis (phagocytic
clearance of apoptotic cells) has been suggested to lead to
the accumulation of apoptotic cells and may perpetuate
inflammation via secondary necrosis.47 In addition, we
evaluated the presence of another apoptotic marker such
as annexin V in CD8þ T-lymphocytes in samples of
smoking controls and smokers with mild/moderate COPD,
by double immunofluorescence analysis. We found that the
number of CD8þ T-lymphocytes co-localising Annexin V was
lower in smokers with mild/moderate COPD than in smoking
controls confirming that these cells stay longer in the
airway tissue of COPD patients compared with smoking
controls.
Moreover, excluding the severe/very severe COPD cases
that did not show decreased apoptosis of CD8þ T-lympho-
cytes, we found a direct correlation between the reduced
apoptosis of CD8þ T-lymphocytes and the decreased values
of both FEV1 and FEV1/FVC ratio, which supports the
concept that the apoptotic mechanism is unrelated to
cigarette smoking per se although it seems to be an event
that is specifically associated with the development of
COPD.
An apparent confusing element in our study may be that
the presence of cancer may influence the host immune
cells. Accordingly, we have first examined only tissue far
away from the tumor site and we designed the study
including cancer patients with or without COPD and COPD
patients without cancer. The showed results suggest that
smokers with cancer and severe COPD without cancer are
similar in terms of CD8þ cell apoptosis. Differently, we
observed in the patients with COPD and cancer (mild/
moderate COPD) a decreased and not an increased
apoptosis of CD8þ cells suggesting that although cancer
cells may trigger negative signals in CD8þ cells in terms also
of reducing their survival, the presence of COPD promotes
their survival.
In conclusion, the data presented in this study suggest
a possible mechanism by which the immune inflammatory
response in the airways of patients with COPD is maintained
and amplified. A better definition of this mechanism might
lead to the development of new therapeutic strategies to
reduce the number of inflammatory cells in the inner
airway wall and to control the immune inflammatory
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